Skip to content

Study on the mechanism of thyroid hormone mediated opsin expression abnormality in TAO patients

Study on the mechanism of thyroid hormone mediated opsin expression abnormality in TAO patients

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035598
Enrollment
Unknown
Registered
2020-08-14
Start date
2020-08-05
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid associated ophthalmopathy, TAO

Interventions

Sponsors

Ophthalmology Hospital affiliated to Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40-60 years, right handed. 2. Education level >= 5 years, and BMI index, age, gender and education level were matched among the groups. 3. After fully understanding the safety of the research project, willing to actively cooperate with the research and sign the informed consent. 4. Refer to Bartley diagnostic criteria for Tao 5. Diagnostic criteria of Don: Tao patients had the following conditions at the same time: (1) The best corrected visual acuity was less than 20 / 20; (2) Visual field examination showed that the mean defect (MD) value was less than - 5dB; (3) Orbital CT showed orbital apex crowding.

Exclusion criteria

Exclusion criteria: 1. Patients with visual impairment due to refractive media, ametropia, retinal disease, amblyopia, optic atrophy or other non Tao reasons; 2. Color vision abnormality caused by congenital color vision abnormality and other diseases; 3. Patients with history of brain tumor, brain injury or cerebrovascular disease; 4. Patients with nervous system diseases; 5. Patients with poorly controlled diabetes mellitus or severe systemic diseases such as heart, liver and kidney insufficiency; 6. Patients with a history of mental illness or family history; 7. Patients with other metabolic diseases such as diabetes mellitus; 8. Patients who cannot cooperate with CCT due to dark area of visual field center or other factors.

Design outcomes

Primary

MeasureTime frame
AO-OCT;CCT;T3, T4, TSH, TRAB;

Secondary

MeasureTime frame
OCT;Orbital CT;Visual Field;

Countries

China

Contacts

Public ContactTu Yunhai

Ophthalmology Hospital affiliated to Wenzhou Medical University

23200469@qq.com+86 13858851159

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026